You are here: Industry Insights > Cellectis

News List

Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities firstwordpharma
June 15, 2021
Cellectis S.A., a clinical-stage biotechnological company employing its core proprietary technologies to develop products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor (CAR) T-cells in the field of immuno-oncology
FDA Lifts Hold on Multiple Myeloma Study americanpharmaceuticalreview
December 03, 2020
Cellectis announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 1 MELANI-01 trial evaluating the UCARTCS1 product candidate for the treatment of patients with relapsed or refractory multiple myeloma (MM).
Cellectis Appoints Chief Medical Officer americanpharmaceuticalreview
April 16, 2020
Cellectis announced the appointment of Carrie Brownstein, M.D., to the role of Chief Medical Officer.
French biotech Cellectis picks U.S. for commercial CAR-T production fiercepharma
March 13, 2019
Cellectis is building a 14,000-square-foot facility in Paris to produce clinical supplies...
Cellectis reopens the off-the-shelf CAR-T treatment pharmafile
November 09, 2017
Shares in the company spiked initially on the release of the news, before settling at 30 cents higher than before the announcement.
FDA lifts hold on Cellectis’ CAR-T trial, adds go-slow caveat fiercebiotech
November 08, 2017
The FDA has lifted the clinical hold it placed on Cellectis’ CAR-T trials in September following the death of a patient.
FDA holds trials of Cellectis’ cell therapy after patient death pharmatimes
September 06, 2017
US regulators have placed on hold studies of French drugmaker Cellectis’ CAR-T therapy following a patient fatality.